Post-earnings recap
Reported
Mon, Nov 3, 2025
EPS actual
$2.66
EPS est.
$1.12
EPS surprise
+136.87%
1-day move
+0.17%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's strong EPS performance indicates better-than-expected profitability, which contributed to a slight increase in stock price. However, the lack of revenue data and future guidance may leave investors cautious. The stock's modest rise suggests that while investors are pleased with the EPS beat, they are waiting for more comprehensive information on revenue and future plans.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.66 | N/A | +136.87% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook on their projects despite not offering specific future guidance. They emphasized the importance of their ongoing research efforts.
Management highlighted strong performance in their ongoing projects.
They expressed confidence in their pipeline but did not provide specific guidance.
The team is focused on maintaining momentum in research and development.